Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Sodium Phenylbutyrate Plus Azacytidine
NCT00006019Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate, azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2000; status: completed.
02
Drugs
sodium phenylbutyrateazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00006019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006019.